&w=3840&q=100)
D2C insurer ACKO brings MS Dhoni on board as investor and brand ambassador
Reinventing insurance: Technology meets trust
ACKO was founded in 2016 by Varun Dua with the goal of eliminating friction and pain points that Indian consumers typically experience with traditional insurers. Through its D2C model, ACKO offers auto, health and travel insurance, all managed online without cumbersome paperwork. The company's rapid ascent can be seen in its reach—serving more than 70 million customers and processing upward of 2 million claims annually across various segments.
With this collaboration, Dhoni provides not just his stature but his credibility as someone who resonates with trust, innovation and discipline—all traits aligned with ACKO's brand ethos. Company founder Varun Dua expressed that Dhoni epitomises the values that drive ACKO, especially the focus on customer-first thinking, simplicity and a willingness to challenge industry conventions. He believes Dhoni's involvement reinforces their vision to make insurance engaging and relatable.
A shared vision for modern India
For Dhoni, who is also an automobile enthusiast, the decision was driven by ACKO's transparency and seamless digital-native processes. He noted that insurance is often seen as complicated, but believes ACKO brings 'clarity where there was confusion', and offers a tech-first approach that mirrors the expectations of young, progressive Indians. This alignment, he suggested, is about helping insurance evolve into something people actually trust and appreciate.
Bold moves, expanding horizons
In recent years, ACKO has made significant inroads by diversifying its offerings, including gaining a life insurance licence in 2023 and introducing innovative products like the Flexi Term Life Insurance Plan. Furthering its reach, the company acquired health-tech start-ups Parentlane and OneCare to strengthen its health insurance business. Strategic partnerships with leading platforms such as PhonePe, MyGate, Oyo, redBus and Zomato also reflect ACKO's ambition to become a household name in embedded insurance.
Additionally, ACKO's group health insurance strategy is gaining momentum, with over 200 new-age companies, including Swiggy, Razorpay and CRED, already offering its coverage to employees.
Charting a new path
With Dhoni on board, ACKO's journey to 'rewrite the playbook' for insurance in India gets a formidable boost. This collaboration marks yet another bold move in ACKO's story, underscoring its resolve to make insurance straightforward, customer-focused, and truly loved by the people it serves.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 minutes ago
- Time of India
Trump calls India's economy 'dead' – but that makes no sense
Recently, Donald Trump, the former U.S. President, made fun of India's economy by calling it 'dead.' But that's a strange and silly thing to say. Think about it: An economy is alive as long as people are buying, selling, and trading things — even if it's just one person giving a teabag to a friend in exchange for some biscuits. That's still trade! India has over 1.4 billion people, which means there are tons of trades and businesses happening every second. So how can it be 'dead'? Also, if India's economy was really dead, why is Trump so eager to sell things like soybeans, corn, and butter to India? You don't trade with something that isn't working. He even spent four months trying to make a trade deal — and only gave up when he got frustrated and added extra taxes (called tariffs) on Indian goods. India's economy is actually growing faster than any other big country's right now. That's not what a dead economy looks like. Even countries that aren't growing fast — like Japan — are still very much alive and running. Trump has said strange things before. Once, he told a man his father would be proud 'looking down on him,' thinking the father had passed away. But the man said his dad was still alive. Trump just replied, 'Then he's even more proud!' So when Trump says 'dead,' it might not mean what you think — or it might not mean anything at all. Facebook Twitter Linkedin Email Disclaimer Views expressed above are the author's own.
Mint
2 minutes ago
- Mint
India unveils first formal rules for drug approval panels in regulatory overhaul
New Delhi: India has issued its first formal playbook for how expert panels should vet new drugs, biologics and medical devices—a move aimed at fixing long-standing concerns about inconsistent and opaque approvals that have delayed critical drug launches and eroded industry trust in the regulatory system. The guidelines, issued by the Central Drugs Standard Control Organization (CDSCO), represent a major overhaul of India's drug approval process and aim to make regulatory decisions faster, more predictable and transparent, according to two government officials and documents reviewed by Mint. The guidelines standardize how Subject Expert Committees (SECs) are formed, how members are selected, and how they must evaluate applications, including the scientific benchmarks and disclosure norms they must follow. The SECs advise the Drugs Controller General of India (DCGI) on whether to clear new drugs, and their decisions have long shaped the trajectory of India's pharmaceutical industry. The CDSCO finalized the guidelines about two weeks ago and circulated them to SEC members for immediate implementation, the officials said. The overhaul follows recommendations from the World Health Organization (WHO), which last year conducted a regulatory review of CDSCO and the office of the DCGI, who heads the organization. The WHO called for stronger transparency and data integrity to align India's system with global standards. India's pharmaceutical industry ranks third globally by volume and 14th by value. It accounts for roughly 20% of the world's generic drug supply and manufactures more than 60,000 products across 60 therapeutic areas. The sector also includes over-the-counter drugs, vaccines, contract manufacturing, biologics and biosimilars. As part of its findings, the WHO urged Indian authorities to implement stronger controls to prevent, detect, and respond to substandard and falsified medical products; to launch a market surveillance program for drug quality monitoring; and to ensure that promotional and advertising claims for medicines are not misleading. These steps are now being implemented by the DCGI and other stakeholders involved in the SEC meetings, according to the officials cited earlier. The SECs play a central role in India's drug approval process, advising the DCGI on whether to approve new drugs, biologics, and medical devices. Each committee includes eight experts—one pharmacologist and seven specialists from research, medical, or regulatory institutions—and requires a four-member quorum to issue recommendations. In the absence of formal guidelines, though, these decisions were often viewed as inconsistent or opaque, delaying product approvals. 'SECs are subject expert committees involved in evaluating approvals of new drugs. Simplification and streamlining the process will help industry in getting drugs approved with predictable speed and more transparency. We appreciate the step taken by DCGI," said Dr. Viranchi Shah, national spokesperson of the Indian Drugs Manufacturers Association (IDMA). Emailed queries to the spokesperson for the health ministry went unanswered at the time of publishing. Clearer mandate, tougher benchmarks According to the guidance document, SEC members must meet strict selection criteria, including a publication record of at least 10 peer-reviewed papers and a citation ratio of 2:1. Experts are appointed for a three-year term and are expected to maintain confidentiality, impartiality, and active participation. Those who fail to attend meetings regularly may be removed. The document specifies that SECs must offer rigorous, science-based evaluations on safety, efficacy, and risk-benefit balance. It outlines the dos and don'ts of deliberations: clinical trial waiver decisions must include clear yes/no recommendations with detailed justifications, and all discussions must remain focused on scientific and regulatory issues, excluding matters such as pricing. 'For new drug and clinical trial applications, the DCGI refers them to the SEC, an expert body that discusses proposals and offers recommendations for approval or rejection. These experts, being external to CDSCO, are not always fully aware of regulatory requirements. This often led to differing, sometimes subjective opinions, a lack of uniformity in decisions, and delays on straightforward matters. Therefore, it's important for the committee to provide uniform decisions, maintain transparency, and offer proper reasoning for approvals and rejections," said one of the two government officials cited earlier, who asked not to be named. The second official added, 'There were persistent discussions during SEC meetings about the absence of a guiding document to regulate or suggest proper functioning. This new guidance note outlines the 'do's and don'ts' for experts. Previously, some companies had even alleged that SEC meetings were not being conducted properly." While officials declined to cite specific past incidents, people familiar with the matter said the lack of consistency and alignment among SEC experts, who advise on key regulatory decisions, had severely affected the functioning of the DCGI in recent years. Industry seeks consistency For years, pharmaceutical companies have raised concerns over the unpredictability of SEC verdicts, especially around clinical trial waivers, which are critical for expediting the launch of generics and biosimilars. The new rules aim to reduce such uncertainty by standardizing decision-making across similar products, unless clear scientific reasons justify a deviation. The document states: 'The SECs are indispensable in the CDSCO's evaluation process due to their specialized expertise, independent perspective and commitment to quality assurance. These committees address complex scientific and regulatory challenges, fostering informed decision-making. By operating transparently and consistently across applications, SECs bolster public trust while safeguarding public health and promoting innovation in the healthcare sector." Public health experts have welcomed the reform. 'Any committee should operate under certain guidance, and it is always beneficial for all members of such a committee to have clarity and a common vision. It's akin to laying down the rules of the game," said Dr. Chandrakant Lahariya, a physician and public health expert. He added: 'The Subject Expert Committee (SEC) is an essential requirement for guiding the drug approvals and other processes in all regulatory bodies. When a new drug is needed, the SEC provides its recommendations to the apex drug regulator. CDSCO is a regulatory organization, and they need guidance from a technical expert committee to make decisions. A regulatory body needs guidance from those who deeply understand the subject."
United News of India
15 minutes ago
- United News of India
After bowlers script Eng collapse, Jaiswal keeps India afloat
London, Aug 1 (UNI) Fortunes swing wildly as India rode on Yashasvi Jaiswal's audacious fifty to roar back on a volatile day two of the fifth Test at The Oval by bowling England out for 247 in their first innings and responding with an assertive 75/2 at stumps. England, resuming post-lunch at a commanding 109/1, imploded spectacularly to 215/7 by Tea, undone by a relentless Indian bowling unit. Mohammed Siraj and Prasidh Krishna spearheaded the counterattack with sustained hostility and timely strikes. Zak Crawley's fluent 64 off 57 balls (14x4) ended with a mistimed heave off Prasidh, caught by Jadeja at mid-wicket — the moment that cracked England's momentum. Siraj, then claimed Ollie Pope leg before after a successful DRS challenge, and removed Joe Root soon after in a mirror dismissal — a sharp inswinger pinned him in front and India had their man. Jacob Bethell was then undone by a searing yorker, falling LBW to Siraj. Prasidh Krishna removed Jamie Smith with a rising delivery to second slip, and followed it up by trapping Jamie Overton LBW with a sharp in-dipper, a review confirming the wicket after England burned one earlier in the same over. Harry Brook alone resisted with flair and fight. He struck Siraj for a stunning sweep-scoop six — reminiscent of Rishabh Pant — then raised his 50 in style with a pair through long-off. He reached 53 off 64 balls (5x4, 1x6), but fell in Siraj's final over — an inside edge crashing into the stumps. Chris Woakes, nursing an injury, did not come out to bat, and England were bowled out for 247 in 51.2 overs. Siraj (4/86) and Prasidh (4/62) led India's charge, ably supported by Akash Deep and Jadeja's pressure. India's response was full of intent. Despite the early loss of KL Rahul for 7 — caught by Root off Tongue after multiple teasing away-seamers — Jaiswal launched into England's bowlers with authority. He tore into Atkinson and Tongue with crisp drives, ramps, and cuts. His 50 came off 44 balls, capped with a ramp six over the keeper off Overton. England dropped him twice — Liam Dawson at long leg and Brook in slips — adding to their frustration. Sai Sudharsan was edgy, surviving a dropped chance before falling LBW to Atkinson for 11. His review was in vain, and the dismissal sparked an exchange with Duckett, requiring intervention from Brook and Pope. Akash Deep, sent in as nightwatchman, got off the mark with a boundary and remained unbeaten on 4 at stumps alongside Jaiswal (51*), who had taken India into the lead with a flurry of boundaries, including three in one over from Atkinson. India closed the day at 75/2 in 18 overs, leading England by 52 runs, and Jaiswal looking ominous. With Jaiswal in fine touch and the pitch easing out, Day 3 promises high-stakes drama in this finely poised series decider. Score Summary: England 1st Innings: 247 all out in 51.2 overs (Brook 53, Siraj 4/86, Prasidh 4/62); India 1st Innings: 75/2 in 18 overs (Jaiswal 51*, Atkinson 1/26, Tongue 1/25). UNI BDN SSP
